Celadon Pharmaceuticals Plc

AIM:CEL Stock Report

Market Cap: UK£12.0m

Celadon Pharmaceuticals Valuation

Is CEL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CEL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CEL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CEL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CEL?

Key metric: As CEL barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CEL. This is calculated by dividing CEL's market cap by their current book value.
What is CEL's PB Ratio?
PB Ratio5x
BookUK£2.43m
Market CapUK£12.05m

Price to Book Ratio vs Peers

How does CEL's PB Ratio compare to its peers?

The above table shows the PB ratio for CEL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average16.2x
KNB Kanabo Group
1xn/aUK£5.7m
STX Shield Therapeutics
49.8x84.4%UK£21.5m
N4P N4 Pharma
1.7xn/aUK£2.1m
FUM Futura Medical
12.3x188.3%UK£96.3m
CEL Celadon Pharmaceuticals
5xn/aUK£12.0m

Price-To-Book vs Peers: CEL is good value based on its Price-To-Book Ratio (5x) compared to the peer average (16.2x).

Price to Book Ratio vs Industry

How does CEL's PB Ratio compare vs other companies in the GB Pharmaceuticals Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
EAH ECO Animal Health Group
0.6x39.2%US$60.30m
OCTP Oxford Cannabinoid Technologies Holdings
0.6x15.1%US$1.60m
NFX Nuformix
0.1xn/aUS$513.22k
No more companies available in this PB range
CEL 5.0xIndustry Avg. 2.3xNo. of Companies4PB03.67.210.814.418+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: CEL is expensive based on its Price-To-Book Ratio (5x) compared to the European Pharmaceuticals industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is CEL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CEL PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CEL's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 18:36
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Celadon Pharmaceuticals Plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution